Trial Profile
A Non-Randomised, Open Label, Pilot Trial of Sirolimus Therapy for Segmental Overgrowth Due to PIK3CA Related Overgrowth
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 20 Mar 2019
Price :
$35
*
At a glance
- Drugs Sirolimus (Primary)
- Indications Growth disorders
- Focus Therapeutic Use
- Acronyms PROMISE
- 17 Mar 2019 Status changed from recruiting to completed.
- 05 Apr 2016 New trial record